Clinical Trial Results:
Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blind, double - dummy, parallel group, placebo-controlled study (MERISUDD study)
Summary
|
|
EudraCT number |
2016-004159-56 |
Trial protocol |
IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Nov 2022
|
First version publication date |
02 Nov 2022
|
Other versions |
|
Summary report(s) |
EudraCT_notification_19Sep2022 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.